Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?

Metastatic urothelial carcinoma (mUC) is an aggressive malignancy with a dismal prognosis. Enfortumab vedotin (EV) is an antibody-drug conjugate consisting of an antibody targeting Nectin-4. This protein is highly expressed in UC cells. After binding, monomethyl auristatin E is released into cells,...

Full description

Bibliographic Details
Main Authors:	Brigida Anna Maiorano, Martina Catalano, Evaristo Maiello, Giandomenico Roviello
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-09-01
Series:	Frontiers in Oncology
Subjects:	enfortumab vedotin ADC antibody-drug conjugate nectin-4 urothelial carcinoma bladder cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1254906/full

Similar Items

Increased expression of ATP‐binding cassette transporters in enfortumab vedotin‐resistant urothelial cancer
by: Mariko Kotono, et al.
Published: (2024-03-01)

Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin
by: Takamasa Homma, et al.
Published: (2023-10-01)

Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort
by: Stefanie Zschäbitz, et al.
Published: (2023-07-01)

Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin
by: Jain RK, et al.
Published: (2020-09-01)

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
by: Moussa M, et al.
Published: (2021-02-01)

Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin
by: Shafique MA, et al.
Published: (2023-07-01)

Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
by: Bunpei Isoda, et al.
Published: (2023-06-01)

First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure
by: Bożena Sikora-Kupis, et al.
Published: (2024-01-01)

Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
by: Takashi Kawahara, et al.
Published: (2023-08-01)

Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer
by: Tanya Jindal, et al.
Published: (2023-04-01)

Metastatic bladder cancer forming a sigmoidorectal fistula after enfortumab vedotin therapy: a case report
by: Shinji Tamada, et al.
Published: (2023-11-01)

Desquamative extravasation reaction secondary to enfortumab vedotin
by: Akshay N. Pulavarty, MD, MPH, et al.
Published: (2024-04-01)

First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients
by: Christof Vulsteke, et al.
Published: (2023-03-01)

Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma
by: Nobuaki Matsubara, et al.
Published: (2023-02-01)

Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions
by: Yuki Endo, et al.
Published: (2024-01-01)

Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
by: Thibodeau A, et al.
Published: (2021-10-01)

Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study
by: Akinori Minato, et al.
Published: (2024-02-01)

Case Report: Safety and Efficacy of Enfortumab Vedotin in a Patient With Metastatic Urothelial Carcinoma Undergoing Peritoneal Dialysis
by: Kaylyn R. Collette, et al.
Published: (2022-05-01)

Successful treatment with enfortumab–vedotin of metastatic signet ring cell cancer expressing nectin‐4 and originating from the bladder
by: Maria Aoki, et al.
Published: (2024-03-01)

The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis
by: Michal Sarfaty, et al.
Published: (2021-11-01)

Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside
by: Antonio Ungaro, et al.
Published: (2022-02-01)

Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
by: Jiazheng Yu, et al.
Published: (2023-07-01)

The successful management of SJS/TEN secondary to enfortumab vedotin therapy
by: Rhea Singh, BS, et al.
Published: (2022-06-01)

Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinoma
by: Christina D. Enescu, BS, et al.
Published: (2022-03-01)

Enfortumab Vedotin–related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature
by: Evangelia Vlachou, et al.
Published: (2023-03-01)

Diabetic Ketoacidosis and Acute Kidney Injury Associated With Enfortumab Vedotin for Urothelial Carcinoma: A Case Report
by: Francis Atemnkeng, et al.
Published: (2023-12-01)

Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer
by: Blaine Brower, et al.
Published: (2024-04-01)

Effect of Enfortumab Vedotin Dose Adjustment on Efficacy in Metastatic Urothelial Carcinoma: A Retrospective Single-Center Experience 
by: Clennon A, et al.
Published: (2023-11-01)

Enfortumab vedotin toxic epidermal necrolysis–like blistering dermatosis: A case series and review of the literature
by: Bushra Khanjar, MD, et al.
Published: (2024-01-01)

Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma
by: Eisuke Tomiyama, et al.
Published: (2020-07-01)

Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?
by: Marco Audisio, et al.
Published: (2022-05-01)

Changing Paradigms in the Treatment of Advanced Urothelial Carcinoma: A 2020 Update
by: Alvin Jun Xing Lee, et al.
Published: (2020-12-01)

Cutaneous reactions with enfortumab vedotin: A case series and review of the literature
by: Allison S. Dobry, MD, et al.
Published: (2021-08-01)

NECTIN4 Expression in Extramammary Paget’s Disease: Implication of a New Therapeutic Target
by: Maho Murata, et al.
Published: (2020-08-01)

A rare presentation of enfortumab vedotin–induced toxic epidermal necrolysis
by: Andrea Francis, BS, et al.
Published: (2021-01-01)

Systemic Treatment-Decision Algorithms in Muscle-Invasive Bladder Cancer: Clinical Complexities and Navigating for Improved Outcomes
by: Giles M, et al.
Published: (2023-07-01)

Characterization of cutaneous adverse events to enfortumab vedotin: A retrospective case-control study
by: Ahmad Shahin, BS, et al.
Published: (2023-03-01)

Case report: Enfortumab vedotin induced refractory DKA and multi organ failure – a rare fatal adverse event
by: Astha Koolwal Kapoor, et al.
Published: (2024-02-01)

Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context
by: Hoffman-Censits J, et al.
Published: (2022-12-01)

Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
by: Catherine C. Fahey, et al.
Published: (2023-11-01)